These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 9198218

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Molecular basis of von Willebrand disease and its clinical implications.
    Haematologica; 2004 Sep; 89(9):1036. PubMed ID: 15377463
    [No Abstract] [Full Text] [Related]

  • 4. [Willebrand disease].
    Lequièvre V.
    Rev Infirm; 2006 Sep; (122):22-4. PubMed ID: 16881452
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.
    Franchini M, Mannucci PM.
    Expert Rev Hematol; 2016 Sep; 9(9):825-30. PubMed ID: 27427955
    [Abstract] [Full Text] [Related]

  • 9. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA.
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [Abstract] [Full Text] [Related]

  • 10. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 11. [Variant type von Willebrand disease with defective binding to factor VIII].
    Shima M.
    Ryoikibetsu Shokogun Shirizu; 1998 Jan; (21 Pt 2):430-3. PubMed ID: 9833534
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Acquired von Willebranol syndrome--its pathophysiology, diagnosis and treatment].
    Mohri H.
    Rinsho Ketsueki; 2001 Jul; 42(7):525-36. PubMed ID: 11524842
    [No Abstract] [Full Text] [Related]

  • 16. Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
    Schwarz HP, Dorner F, Mitterer A, Mundt W, Schlokat U, Pichler L, Turecek PL.
    Wien Klin Wochenschr; 1999 Mar 12; 111(5):181-91. PubMed ID: 10226348
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E, Windyga J, European Wilate Study Group.
    Haemophilia; 2009 Jan 12; 15(1):122-30. PubMed ID: 19149848
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.